



A novel anticancer drug for topoisomerase targeting

PI : Dr. Tsai-Kun Li

Professor of Microbiology and Associate Dean, Director, Office for International Affairs, College of Medicine, Chief Executive Officer, Center for Genomic Medicine, National Taiwan University, Taiwan; tsaikunli@ntu.edu.tw

Market Needs:

Small molecule anticancer drug, side effect Relief drug

Our Technology:

This technology is mainly on the innovative development of a new generation of anti-topoisomerase II drugs with the world-leading research and development platforms and this leading to the development of high efficacy and low side effects of new tumor drugs. The selectivity of drug therapy for diseases is a very important topic in the field of pharmacology – higher therapeutic index. Our studies showed that DNA topoisomerase anticancer drugs in selective in tumor killings and thus a potential source of anticancer drugs with a great therapeutic index. It is worth noting that human cells have two isoenzymes of the type II DNA topoisomerase, and our and other recent studies found that the drug-induced hTop2 α -targeting is mainly responsible for anti-cancer efficacy and targeting hTop2 β is the cause for the clinical adverse effects, such as cardiac toxicity. Thus, the hTop2 α -specific anticancer drugs and hTop2 β -specific antagonists will all have clinical advantages. As a result of drug development programs, cancer patients will have greater opportunities for survival and our leads, in the global market for cancer drugs, shall also be quite competitive. The research team is very capable, combined with molecular pharmacology, cell biochemistry and medicinal chemistry and other expertise, and has established the world's leading drug development platforms and the isoenzyme-specific assays and animal experiments.

Strength:

Technology transfer is feasible, so that the new machine to develop new drugs against cancer and antagonists to reduce side effects will bring great opportunities for patients to be treated, and it is quite competitive in the global market for oncology drugs.

Competing Products:

Etoposide 、Doxorubicin 、Mitoxantrone

Intellectual Properties:

- (1) Our patent related to this technology (US_8765443_B2).
- (2) This research team has decades of research experience for this technology.

Contact (do not need to fill out):

Center for Industry-Academia Cooperation, NTU

Tel: 02-3366-9945, E-mail: ntuciac@ntu.edu.tw